VIP (Vasoactive Intestinal Peptide)
|VIP (Vasoactive Intestinal Peptide)|
|Molar Mass||3326.8 g/mol|
VIP, or Vasoactive Intestinal Peptide, is a neuropeptide with diverse physiological functions. In the realm of research, VIP is explored for its potential applications and benefits, emphasizing its role in various bodily processes.
VIP is known for its vasodilatory properties, impacting blood flow regulation, and its presence in multiple tissues, including the nervous and digestive systems. As a signaling molecule, VIP engages in complex interactions, making it a subject of interest in scientific investigations.
Researchers are actively studying VIP due to its involvement in several biological pathways. From the cardiovascular system to neural function, VIP’s wide-ranging effects make it a versatile candidate for understanding and potentially influencing physiological responses.
VIP on Penile Erection
VIP’s vasodilatory effects extend to the vascular system, including blood vessels within the penile region. Studies have explored the potential of VIP in promoting penile erection by facilitating increased blood flow to erectile tissues. This research avenue holds promise for insights into erectile dysfunction mechanisms.
VIP on Neurodegenerative Disorders
VIP’s neuroprotective properties have prompted investigations into its potential role in mitigating neurodegenerative disorders. Studies suggest that VIP may exert protective effects on neurons, offering a potential avenue for therapeutic interventions in conditions such as Alzheimer’s and Parkinson’s diseases.
VIP on Obesity
The influence of VIP on metabolic processes has led researchers to explore its impact on obesity. Preliminary studies indicate that VIP may play a role in modulating appetite and energy metabolism, making it a candidate for further investigation in the context of obesity research.
VIP, as a vasoactive neuropeptide, demonstrates multifaceted effects on various physiological systems. Ongoing research is unraveling its potential applications, from addressing erectile dysfunction to exploring neuroprotective avenues and potential implications in obesity-related mechanisms. It is crucial to approach this research with a focus on understanding VIP’s intricate interactions and their implications for future therapeutic developments.
- Edmund A. Willis, Bent Ottesen, Gorm Wagner, Frank Sundler, Jan Fahrenkrug,
Vasoactive intestinal polypeptide (vip) as a putative neurotransmitter in penile erection, Life Sciences, Volume 33, Issue 4, 1983, Pages 383-391,ISSN 0024-3205, https://doi.org/10.1016/S0024-3205(83)80013-7. [Read More].
- Vu, J.P., Larauche, M., Flores, M. et al. Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP). J Mol Neurosci 56, 377–387 (2015). https://doi.org/10.1007/s12031-015-0556-z. [Read More].
- Delgado, M. and Ganea, D. (2003), Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J, 17: 1-17. https://doi.org/10.1096/fj.02-1029fje. [Read More].